Aussie doc: St. Jude’s hypertension treatment better than Medtronic’s
When it comes to commercialization efforts of renal denervation therapy, St. Jude Medical (NYSE:STJ) is […]
View ArticleJohns Hopkins spinoff designs a better vascular access port for kidney...
For the more than 870,000 patients in the U.S. being treated for end-stage renal disease, […]
View Article
More Pages to Explore .....
